Return to news


Quebec City, Quebec, May 05, 2017 Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has today announced the departure of Mr. Thierry Dumas, Chief Financial Officer and Corporate Secretary. Mr. Dumas will leave the Company on May 12, 2017.

Mr. Louis Laflamme, Opsens’ current President and Chief Executive Officer, will assume the interim position of Chief Financial Officer and until further notice. Mr. Laflamme was Opsens’ Chief Financial Officer between 2005 and 2013, before he was named President and Chief Executive Officer.

Commenting on the upcoming change, Opsens’ President and Chief Executive Officer, Mr. Louis Laflamme stated:  “Thierry has helped create shareholders value over the last 5 years. On behalf of the Board of Directors and the entire Opsens team, I thank him for his contribution and wish him success in his future endeavours”. “Despite Thierry’s departure, I have great confidence in existing finance team supporting continuous growth of the Company,” added Mr. Laflamme.

Opsens aims to become a key player in the guidewire FFR market with the OptoWire, a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire that provides optimal performance to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources, the FFR market represented more than US$300 million in sales in 2014 and is expected to reach US$1 billion in the medium-term.

About Opsens Inc. (www.opsens.com or www.opsensmedical.com)

Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications, such as the monitoring of oil wells and other demanding industrial applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

 Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.


For further information, please contact: Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333